Janus-activated kinase 2 inhibitors: A new era of targeted therapies providing significant clinical benefit for philadelphia chromosome-negative myeloproliferative neoplasms

Srdan Verstovsek

Research output: Contribution to journal › Editorial › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Janus-activated kinase 2 inhibitors: A new era of targeted therapies providing significant clinical benefit for philadelphia chromosome-negative myeloproliferative neoplasms'. Together they form a unique fingerprint.